Welcome to our dedicated page for Spyre Therapeutics SEC filings (Ticker: SYRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Spyre Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Spyre Therapeutics's regulatory disclosures and financial reporting.
Spyre Therapeutics, Inc. reported a routine insider equity award involving director Tomas Kiselak and Fairmount-affiliated funds. An option was granted covering 8,026 shares of common stock at an exercise price of $72.51 per share, expiring on May 27, 2036. The option vests in full on the earlier of May 27, 2027 or the company’s 2027 annual stockholder meeting, subject to Mr. Kiselak’s continued service. Under his arrangement with Fairmount Funds Management LLC, any net cash or stock from this option is for the benefit of Fairmount-managed investment vehicles, and Mr. Kiselak disclaims beneficial ownership except for his pecuniary interest.
Spyre Therapeutics, Inc. director Jeffrey W. Albers received a stock option grant covering 8,026 shares of common stock. The option has an exercise price of $72.51 per share and expires on May 27, 2036.
The award vests and becomes fully exercisable upon the earlier of May 27, 2027 or the date of Spyre Therapeutics' 2027 annual meeting of stockholders, as long as Albers continues serving the company through that vesting date. Following this grant, he holds options for 8,026 shares directly.
Spyre Therapeutics, Inc. director Michael Thomas Henderson received a grant of stock options covering 8,026 shares of common stock. The options have an exercise price of $72.51 per share and expire on May 27, 2036. They vest and become fully exercisable on the earlier of May 27, 2027 or the company’s 2027 annual meeting of stockholders, subject to his continued service, leaving him with 8,026 options following this award.
Spyre Therapeutics, Inc. director Laurie Stelzer received a grant of stock options covering 8,026 shares of common stock. The options carry an exercise price of $72.51 per share and expire on May 27, 2036.
The award will vest and become fully exercisable upon the earlier of May 27, 2027 or the date of Spyre Therapeutics' 2027 annual meeting of stockholders, as long as Stelzer continues to serve the company through that vesting date. Following this grant, she holds 8,026 options directly.
Spyre Therapeutics, Inc. director Mark C. McKenna received a grant of stock options covering 8,026 shares of common stock. These options carry an exercise price of $72.51 per share and expire on May 27, 2036.
The options will vest and become fully exercisable upon the earlier of May 27, 2027 or the date of Spyre Therapeutics’ 2027 annual meeting of stockholders, provided McKenna continues serving the company through the vesting date. After this grant, he holds 8,026 derivative securities directly from this award.
Spyre Therapeutics, Inc. director Sandra Milligan received a grant of stock options covering 8,026 shares of common stock. The options have an exercise price of $72.51 per share and expire on May 27, 2036. They vest and become fully exercisable on the earlier of May 27, 2027 or the company’s 2027 annual stockholder meeting, contingent on her continued service.
Spyre Therapeutics, Inc. reported results from its Annual Meeting of Stockholders held on May 27, 2026. Stockholders elected three Class I directors — Mark McKenna, Cameron Turtle and Laurie Stelzer — to serve until the 2029 annual meeting. They also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers and ratified KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026. In addition, stockholders approved the company’s amended and restated 2016 Employee Stock Purchase Plan, which provides a refreshed framework for employee share purchases. Effective the same day, director Peter Harwin resigned from the board, and the board size was reduced from eight to seven directors; his resignation was not due to any disagreement with the company.
Spyre Therapeutics, Inc. director Michael Thomas Henderson reported open-market sales of a total of 80,000 shares of common stock on May 8, 2026. The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 6, 2026.
The sales were broken into four trades at weighted average prices between about $72.57 and $75.35 per share. Footnotes state that each reported price is a weighted average, with individual trades occurring in ranges from $72.03 up to $75.71 per share.
Spyre Therapeutics reported first quarter 2026 results showing continued investment in its pipeline and a larger net loss. Net loss was $69.0 million compared with $44.8 million a year earlier, driven by higher R&D and G&A spending and a swing to other expense from prior-year income.
R&D rose to $60.4 million as manufacturing, clinical trial activity, and headcount increased. G&A reached $15.2 million. The company recorded a $30.0 million gain tied to FDA approval milestones from a prior asset sale, partly offset by higher contingent value right liability, which contributed to $23.4 million in other expense. Spyre ended March 31, 2026 with $741.5 million in cash, cash equivalents, and marketable securities, and reported $1,176.8 million of pro forma cash including April 2026 equity offering proceeds, which it expects will fund operations into the second half of 2029.